This work is licensed under a Creative Commons Attribution 4.0 International License.
EB(H2R)-lytic
General Information
DRACP ID DRACP01407
Peptide Name EB(H2R)-lytic
Sequence YRWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK
Sequence Length 32
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP Cancer targeted peptides
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| H322 | Minimally invasive lung adenocarcinoma | Carcinoma | IC50=3.2μM | WST-8 assay | 72h | Patent |
| BT-20 | Invasive breast carcinoma of no special type | Carcinoma | IC50=1.9μM | WST-8 assay | 72h | Patent |
| U251 | Astrocytoma | Carcinoma | IC50=8.4μM | WST-8 assay | 72h | Patent |
| BXPC-3 | Pancreatic ductal adenocarcinoma | Carcinoma | IC50=6.6μM | WST-8 assay | 72h | Patent |
| SU.86.86 | Pancreatic adenocarcinoma | Carcinoma | IC50=7.4μM | WST-8 assay | 72h | Patent |
| LNCaP | Prostate carcinoma | Carcinoma | IC50=4.8μM | WST-8 assay | 72h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity MRC-5: IC50>20μM; HEK293: IC50>20μM
Target Epidermal growth factor receptor (EGFR)
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification l=D-Leucine; k=D-Lysine
Chiral Mix
Physicochemical Information
Formula C153H239N39O29
Absent amino acids ACDEFHMS
Common amino acids KL
Mass 364195
Pl 10.91
Basic residues 7
Acidic residues 0
Hydrophobic residues 9
Net charge 7
Boman Index -1882
Hydrophobicity -37.81
Aliphatic Index 94.38
Half Life
/
Extinction Coefficient cystines 9970
Absorbance 280nm 321.61
Polar residues 9
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2011/0319336 A1
Patent Title Selective anticancer chimeric peptide.
Other Iinformation Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status: Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013
Other Published ID CN102238965A EP2370107A2 WO2010064207A2 WO2010064207A3
This work is licensed under a Creative Commons Attribution 4.0 International License.